Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | L'Oréal SA | 311 |
| 2 | Bayer AG | 67 |
| 3 | Cyclerion Therapeutics Inc | 65 |
| 4 | Roche Holding AG | 59 |
| 5 | Nissan Chemical Corp | 57 |
| 6 | Ironwood Pharmaceuticals Inc | 53 |
| 7 | Nicox SA | 52 |
| 8 | Johnson and Johnson | 49 |
| 9 | Bristol Myers Squibb Co | 47 |
| 10 | Redx Pharma Ltd | 43 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 1,684 |
| 2 | A61P | Therapeutic activity (drug indications) | 1,577 |
| 3 | C07D | Heterocyclic compounds | 1,230 |
| 4 | A61Q | Cosmetics, personal care | 573 |
| 5 | C07C | Acyclic and carbocyclic compounds | 354 |
| 6 | Y02A | Climate change adaptation | 238 |
| 7 | C07K | Peptides | 168 |
| 8 | C07F | Organometallic compounds | 145 |
| 9 | A45D | 106 | |
| 10 | A01N | Preservation of bodies; biocides; pest repellents | 102 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Treatment of sexual dysfunction with N-hydroxyguanidine compounds | 2001 | 48 | |
| Substd hydroxyguanidines prepn | 1972 | 26 | |
| Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | 2009 | Heidelberg Pharma AG | 23 |
| N-HYDROXYGUANIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | 2007 | Incyte Corp | 23 |
| Use of hydroxyguanidines | 2003 | 11 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 1 |
| 2023 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Daniel Mansuy | Université Paris Cité | 13 |
| 2 | Jean‐Luc Boucher | Université Paris Cité | 12 |
| 3 | Bernd Clement | Christian-Albrechts-Universität zu Kiel | 6 |
| 4 | Jon M. Fukuto | Oklahoma State University Center for Health Sciences | 4 |
| 5 | David Lefèvre‐Groboillot | Université Paris Cité | 4 |
| 6 | Dennis J. Stuehr | Université Paris Cité | 4 |
| 7 | Maija Dambrova | Uppsala University | 4 |
| 8 | Jarl E. S. Wikberg | Uppsala University | 4 |
| 9 | Karel Chalupský | Centre National de la Recherche Scientifique | 3 |
| 10 | Dennis Schade | Christian-Albrechts-Universität zu Kiel | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Arginase: Structure, Mechanism, and Physiological Role in Male and Female Sexual Arousal | 2005 | 162 | Sexual function and dysfunction studies |
| The Novel Binding Mode of N-Alkyl-N‘-hydroxyguanidine to Neuronal Nitric Oxide Synthase Provides Mechanistic Insights into NO Biosynthesis | 2002 | 116 | Nitric Oxide and Endothelin Effects |
| Chemical oxidation of N-hydroxyguanidine compounds | 1992 | 114 | Nitric Oxide and Endothelin Effects |
| Structure and dynamics of cationic membrane peptides and proteins: Insights from solid‐state NMR | 2011 | 96 | Lipid Membrane Structure and Behavior |
| Microsomal Cytochrome P450 Dependent Oxidation of N-Hydroxyguanidines, Amidoximes, and Ketoximes: Mechanism of the Oxidative Cleavage of Their CN(OH) Bond with Formation of Nitrogen Oxides | 1998 | 89 | Pharmacogenetics and Drug Metabolism |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of hydroxyguanidine?
Which organizations hold the most patents for hydroxyguanidine compounds?
What are the primary therapeutic applications mentioned in hydroxyguanidine patents?
What biochemical mechanisms have been studied for hydroxyguanidine?
How has patent activity for hydroxyguanidine evolved in recent years?